Skip to main content
. 2023 Nov 15;18(11):e0291451. doi: 10.1371/journal.pone.0291451

Table 1. Demographics and baseline characteristics of the enrolled participants.

Sociodemographic characteristics Total CCTA obstructive stenosis SPECT—ischemia
No Yes p No Yes p
N = 956 N = 818 N = 138 N = 818 N = 138
Age–Mean (SD) 61.14 (14.20) 59.97 (14.21) 68.04 (12.05) <0.001 61.02 (14.26) 61.84 (13.87) 0.53
Sex–Female N (%) 439 (46%) 386 (47%) 53 (38%) 0.055 385 (47%) 54 (39%) 0.084
Comorbidities
Hypertension–N (%) 848 (89%) 719 (88%) 129 (93%) 0.055 720 (88%) 128 (93%) 0.10
Diabetes–N (%) 778 (81%) 659 (81%) 119 (86%) 0.11 657 (80%) 121 (88%) 0.040
Dyslipidemia–N (%) 806 (84%) 674 (82%) 132 (96%) <0.001 680 (83%) 126 (91%) 0.015
Heart failure–N (%) 107 (11%) 86 (11%) 21 (15%) 0.10 85 (10%) 22 (16%) 0.056
Ever smoker–N (%) 317 (33%) 257 (31%) 60 (43%) 0.005 263 (32%) 54 (39%) 0.11
Symptoms
Chest pain or shortness of breath–N (%) 537 (56%) 474 (58%) 63 (46%) 0.007 472 (58%) 65 (47%) 0.020
Medication
Aspirin/Clopidogrel–N (%) 768 (80%) 645 (79%) 123 (89%) 0.005 647 (79%) 121 (88%) 0.019
Statin–N (%) 706 (74%) 582 (71%) 124 (90%) <0.001 589 (72%) 117 (85%) 0.002
ACE/ARB–N (%) 625 (65%) 525 (64%) 100 (72%) 0.059 527 (64%) 98 (71%) 0.13
Beta blockers–N (%) 770 (81%) 654 (80%) 116 (84%) 0.26 645 (79%) 125 (91%) 0.001
Calcium channel blockers–N (%) 431 (45%) 359 (44%) 72 (52%) 0.070 369 (45%) 62 (45%) 0.97